IM Cannabis vs Sunshine Biopharma
IM Cannabis and Sunshine Biopharma are similar in size: $39.2m and $36.3m of revenue in their latest fiscal years. Sunshine Biopharma grew faster (4.1% against -0.7%). Sunshine Biopharma kept more of each dollar of sales as profit: a net margin of -16.5% against -20.7%.
| Latest fiscal year | IM CannabisIMCC, 2025 | Sunshine BiopharmaSBFM, 2025 |
|---|---|---|
| Revenue | $39.2m | $36.3m |
| Revenue growth | -0.7% | 4.1% |
| Net income | −$8.1m | −$6.0m |
| Operating margin | -21.2% | -17.2% |
| Net margin | -20.7% | -16.5% |
| Return on equity | — | -25.7% |
| Free cash flow | $3.4m | −$5.5m |
| Cash | $2.0m | $9.1m |
| Total debt | $11.8m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $0 |
| Employees | — | 50 |
| Market value | $4.2m | $6.5m |
| Price vs our value range | — | — |
| Moat score | — | 15 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |